Skip to main content
. 2018 Aug 20;7:212539. doi: 10.7573/dic.212539

Figure 4.

Figure 4

Cumulative percentage of patients with clearing of target lesions following (a) 3 and (b) 5 weeks of treatment with BMVP or BMV cream as evaluated by principal investigator, blinded assessors, and patient self-assessment.27

*p<0.001 versus BMV cream; **p=0.006 versus BMV cream.

BMV, betamethasone valerate; BMVP, betamethasone valerate medicated plaster.